RNF144B Antibody

Polyclonal Antibody

RNF144B

bA528A10.3 antibody, E3 ubiquitin protein ligase RNF144B antibody, E3 ubiquitin-protein ligase RNF144B antibody, IBR domain containing 2 antibody, IBR domain containing protein 2 antibody, IBR domain-containing protein 2 antibody, IBRDC 2 antibody, IBRDC2 antibody, KIAA0161 antibody, MGC71786 antibody, OTTHUMP00000016079 antibody, OTTHUMP00000016080 antibody, OTTHUMP00000039360 antibody, p53 inducible RING finger protein antibody, p53-inducible RING finger protein antibody, p53RFP antibody, PIR2 antibody, R144B_HUMAN antibody, Ring finger 144B antibody, RING finger protein 144B antibody, RNF 144B antibody, RNF144B antibody

Fusion protein of human RNF144B

p53 is the most commonly mutated gene in human cancer identified to date. Expression of p53 leads to inhibition of cell growth by preventing progression of cells from G1 to S phase of the cell cycle. Most importantly, p53 functions to cause arrest of cells in the G1 phase of the cell cycle following any exposure of cells to DNA-damaging agents. The MDM2 (murine double minute-2) protein was initially identified as an oncogene in a murine transformation system. MDM2 functions to bind p53 and block p53-mediated transactivation of cotransfected reporter constructs. The MDM2 gene is amplified in a high percentage of human sarcomas that retain wildtype p53 and tumor cells that overexpress MDM2 can tolerate high levels of p53 expression. Another p53 target protein is the p53-inducible RING finger protein (p53RFP), an auto-ubiquitinylated protein acting as an E3 ubiquitin ligase. p53RFP, also designated IBRDC2 in mouse and rat, receives ubiquitin from specific E2 ubiquitin-conjugating enzymes and transfers it to substrates that promote their degradation by the proteasome. p53RFP may mediate re-entry into the cell cycle.

Antigen Affinity Purified

Cell Biology

Fusion protein of Human RNF144B